Skip to content
1887

Access Microbiology open research platform logo Access Microbiology

Volume 5, Issue 9

One year experience of bacteremia at a tertiary care hospital in Northern India Open Access

Abstract

is a Gram-negative, motile, obligate aerobic and non-fermentative bacterium. It is an emerging pathogen in the hospital environment as it is frequently found in various solutions.

Information about the incidence and risk factors of bacteremia from India is limited.

We conducted this study to identify the risk factors and underlying conditions predisposing to bacteremia by spp. and analyse the antibiotic resistance pattern of the isolates.

We performed a retrospective observational study where automated blood cultures positive for spp. were assessed for clinical characteristics and antibiotic susceptibility patterns from January 2022 to December 2022 in the microbiology laboratory of a tertiary care centre in Northern India.

A total of 14 cases (14/2435, 0.57 %) of spp. were identified from bloodstream infections in one year. The mean age of the patients was 37.59±23.17 years with a male predominance (8/14, 57.1 %). All patients were managed on intravenous antibiotics and intravenous access as peripheral line catheters and only 5(5/14, 35.7 %) patients were managed on central line catheters. The isolates were found highly susceptible to ticarcillin-clavulanic acid (14/14, 100.0 %) followed by fluoroquinolones (12/14, 85.72 %) and trimethoprim-sulphamethoxazole (12/14, 85.72 %). Only 57.14 % (8/14, 57.14 %) of the patients were susceptible to piperacillin-tazobactam. The all-cause 40 day mortality was observed in 35.7 % (5/14, 35.7 %) with two deaths that were directly attributable to sepsis.

This study provides insight into the incidence of bacteremia at our centre and the necessary antibiotic therapy to combat it.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): Achromobacter , Achromobacter bacteremia , antibiotic therapy , catheters , Gram-negative and non-fermentative bacteria
© 2023 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License.
Loading

Article metrics loading...

/content/journal/acmi/10.1099/acmi.0.000588.v3
2023-09-13
2026-03-09

Metrics

Loading full text...

Full text loading...

/deliver/fulltext/acmi/5/9/acmi000588.v3.html?itemId=/content/journal/acmi/10.1099/acmi.0.000588.v3&mimeType=html&fmt=ahah

References

  1. Bergey DH, Harrison FC, Breed RS, Hammer BW, Huntoon FM. Bergey’s manual of determinative Bacteriology, 1st. edn The Williams and Wilkins Co; 1923
     [Google Scholar]
  2. Glupczynski Y, Hansen W, Freney J, Yourassowsky E. In vitro susceptibility of Alcaligenes denitrificans subsp. xylosoxidans to 24 antimicrobial agents. Antimicrob Agents Chemother 1988; 32:276–278 [View Article] [PubMed]
     [Google Scholar]
  3. Yabuuchi E, Yano I, Goto S, Tanimura E, Ito T et al. Description of Achromobacter xylosoxidans Yabuuchi and Ohyama 1971. Int J Syst Bacteriol 1974; 24:470–477 [View Article]
     [Google Scholar]
  4. Saiman L, Chen Y, Tabibi S, San Gabriel P, Zhou J et al. Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. J Clin Microbiol 2001; 39:3942–3945 [View Article] [PubMed]
     [Google Scholar]
  5. Fernández-Olmos A, García-Castillo M, Morosini MI, Lamas A, Máiz L et al. MALDI-TOF MS improves routine identification of non-fermenting Gram negative isolates from cystic fibrosis patients. J Cyst Fibros 2012; 11:59–62 [View Article] [PubMed]
     [Google Scholar]
  6. Kidd TJ, Ramsay KA, Hu H, Bye PTP, Elkins MR et al. Low rates of Pseudomonas aeruginosa misidentification in isolates from cystic fibrosis patients. J Clin Microbiol 2009; 47:1503–1509 [View Article] [PubMed]
     [Google Scholar]
  7. Swenson CE, Sadikot RT. Achromobacter respiratory infections. Ann Am Thorac Soc 2015; 12:252–258 [View Article] [PubMed]
     [Google Scholar]
  8. Amoureux L, Bador J, Fardeheb S, Mabille C, Couchot C et al. Detection of Achromobacter xylosoxidans in hospital, domestic, and outdoor environmental samples and comparison with human clinical isolates. Appl Environ Microbiol 2013; 79:7142–7149 [View Article] [PubMed]
     [Google Scholar]
  9. Duggan JM, Goldstein SJ, Chenoweth CE, Kauffman CA, Bradley SF. Achromobacter xylosoxidans bacteremia: report of four cases and review of the literature. Clin Infect Dis 1996; 23:569–576 [View Article] [PubMed]
     [Google Scholar]
  10. Fujioka M, Oka K, Kitamura R, Yakabe A, Chikaaki N. Alcaligenes xylosoxidans cholecystitis and meningitis acquired during bathing procedures in a burn unit: a case report. Ostomy Wound Manage 2008; 54:48–53 [PubMed]
     [Google Scholar]
  11. Recio R, Brañas P, Martínez MT, Chaves F, Orellana MA. Effect of respiratory Achromobacter spp. infection on pulmonary function in patients with cystic fibrosis. J Med Microbiol 2018; 67:952–956 [View Article] [PubMed]
     [Google Scholar]
  12. Amoureux L, Sauge J, Sarret B, Lhoumeau M, Bajard A et al. Study of 109 Achromobacter spp. isolates from 9 French CF centres reveals the circulation of a multiresistant clone of A. xylosoxidans belonging to ST 137. J Cyst Fibros 2019; 18:804–807 [View Article] [PubMed]
     [Google Scholar]
  13. Talbot NP, Flight WG. Severe Achromobacter xylosoxidans infection and loss of sputum bacterial diversity in an adult patient with cystic fibrosis. Paediatr Respir Rev 2016; 20 Suppl:27–29 [View Article] [PubMed]
     [Google Scholar]
  14. Barragán EP, Pérez JS, Corbella L, Orellana MÁ, Fernández-Ruiz M. Achromobacter Xylosoxidans bacteremia: clinical and Microbiological features in a 10-year case series. Revista Española de Quimioterapia 2018; 268:
     [Google Scholar]
  15. Centers for Disease Control and Prevention n.d https://www.cdc.gov/nhsn/psc/bsi/index.html accessed 1 July 2021
  16. Pandey K, Nautiyal S. Achromobacter: an emerging nosocomial pathogen. Int J Res Med Sci 2019; 7:3090 [View Article]
     [Google Scholar]
  17. Weinstein MP, Reller LB, Murphy JR, Lichtenstein KA. The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. I. Laboratory and epidemiologic observations. Rev Infect Dis 1983; 5:35–53 [View Article] [PubMed]
     [Google Scholar]
  18. Arpi M, Renneberg J, Andersen HK, Nielsen B, Larsen SO. Bacteremia at a Danish university hospital during a twenty-five-year period (1968-1992). Scand J Infect Dis 1995; 27:245–251 [View Article] [PubMed]
     [Google Scholar]
  19. Haug JB, Harthug S, Kalager T, Digranes A, Solberg CO. Bloodstream infections at a Norwegian university hospital, 1974-1979 and 1988-1989: changing etiology, clinical features, and outcome. Clin Infect Dis 1994; 19:246–256 [View Article] [PubMed]
     [Google Scholar]
  20. Kreger BE, Craven DE, Carling PC, McCabe WR. Gram-negative bacteremia. III. Reassessment of etiology, epidemiology and ecology in 612 patients. Am J Med 1980; 68:332–343 [View Article] [PubMed]
     [Google Scholar]
  21. Johansson PJ, Sternby E, Ursing B. Septicemia in granulocytopenic patients: a shift in bacterial etiology. Scand J Infect Dis 1992; 24:357–360 [View Article] [PubMed]
     [Google Scholar]
  22. Vartivarian SE, Papadakis KA, Palacios JA, Manning JT, Anaissie EJ. Mucocutaneous and soft tissue infections caused by Xanthomonas maltophilia. A new spectrum. Ann Intern Med 1994; 121:969–973 [View Article] [PubMed]
     [Google Scholar]
  23. Igra-Siegman YA, Chmel HE, Cobbs CL. Clinical and laboratory characteristics of Achromobacter xylosoxidans infection. J Clin Microbiol 1980; 11:141–145 [View Article] [PubMed]
     [Google Scholar]
  24. Morrison AJ, Hoffmann KK, Wenzel RP. Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a university hospital. J Clin Microbiol 1986; 24:52–55 [View Article] [PubMed]
     [Google Scholar]
  25. Guo SY, Zhou Y, Hu QF, Yao J, Wang H. Procalcitonin is a marker of gram-negative bacteremia in patients with sepsis. Am J Med Sci 2015; 349:499–504 [View Article] [PubMed]
     [Google Scholar]
  26. Glupczynski Y, Hansen W, Freney J, Yourassowsky E. In vitro susceptibility of Alcaligenes denitrificans subsp. xylosoxidans to 24 antimicrobial agents. Antimicrob Agents Chemother 1988; 32:276–278 [View Article] [PubMed]
     [Google Scholar]
  27. Rolston KV, Messer M. The in-vitro susceptibility of Alcaligenes denitrificans subsp. xylosoxidans to 40 antimicrobial agents. J Antimicrob Chemother 1990; 26:857–860 [View Article] [PubMed]
     [Google Scholar]
  28. Turel O, Kavuncuoglu S, Hosaf E, Ozbek S, Aldemir E et al. Bacteremia due to Achromobacter xylosoxidans in neonates: clinical features and outcome. Braz J Infect Dis 2013; 17:450–454 [View Article] [PubMed]
     [Google Scholar]
  29. Nakamoto S, Sakamoto M, Sugimura K, Honmura Y, Yamamoto Y et al. Environmental distribution and drug susceptibility of Achromobacter xylosoxidans isolated from outdoor and indoor environments. Yonago Acta Med 2017; 60:67–70 [PubMed]
     [Google Scholar]
  30. Kar M, Singh R, Dubey A, Sahu C, Patel SS. Achromobacter xylosoxidans subspecies denitrificans endocarditis in a patient with prosthetic aortic valve: a case report and review of literature. J Clin Diagn Res 2022; 16: [View Article]
     [Google Scholar]
  31. Liu C, Pan F, Guo J, Yan W, Jin Y et al. Hospital acquired pneumonia due to Achromobacter spp. in a geriatric ward in China: clinical characteristic, genome variability, biofilm production, antibiotic resistance and integron in isolated strains. Front Microbiol 2016; 7:621 [View Article] [PubMed]
     [Google Scholar]
  32. D’Amato RF, Salemi M, Mathews A, Cleri DJ, Reddy G. Achromobacter xylosoxidans (Alcaligenes xylosoxidans subsp. xylosoxidans) meningitis associated with a gunshot wound. J Clin Microbiol 1988; 26:2425–2426 [View Article] [PubMed]
     [Google Scholar]
  33. Olson DA, Hoeprich PD. Postoperative infection of an aortic prosthesis with Achromobacter xylosoxidans . West J Med 1982; 136:153–157 [PubMed]
     [Google Scholar]
  34. Isler B, Kidd TJ, Stewart AG, Harris P, Paterson DL. Achromobacter infections and treatment options. Antimicrob Agents Chemother 2020; 64: [View Article]
     [Google Scholar]
  35. Bador J, Amoureux L, Blanc E, Neuwirth C. Innate aminoglycoside resistance of Achromobacter xylosoxidans is due to AxyXY-OprZ, an RND-type multidrug efflux pump. Antimicrob Agents Chemother 2013; 57:603–605 [View Article] [PubMed]
     [Google Scholar]
/content/journal/acmi/10.1099/acmi.0.000588.v3
Loading
One year experience of Achromobacter bacteremia at a tertiary care hospital in Northern India
Access Microbiology 5, 000588.v3 (2023); https://doi.org/10.1099/acmi.0.000588.v3
/content/journal/acmi/10.1099/acmi.0.000588.v3
/content/journal/acmi/10.1099/acmi.0.000588.v3
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An error occurred
Approval was partially successful, following selected items could not be processed due to error